| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.024 | 0.6 |